Recent advances in immunotherapy have revealed a promising frontier in Type 1 diabetes treatment: outsmarting rather than ...

Insulin-producing cells injected into a man with type 1 diabetes have survived for a month so far without the need for immune ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchise Biomea preparing icovamenib for late-stage clinical development 2025 corporate update to be presented ...